On February 22nd, 2021, the Food and Drug Administration (FDA) approved Libtayo (cemiplimab-rwlc) for the treatment of advanced non-small cell lung cancer (NSCLC) with no changes in EGFR, ALK, or ROS1 but with high PD-L1. The FDA based their approval on the results of a clinical trial which found that patients receiving Libtayo lived longer, went more time without progression, and were more likely to respond than those receiving platinum based chemotherapy.

Libtayo gives patients with advanced NSCLC and no changes in EGFR, ALK, or ROS1 a new immunotherapy option.

Click here to view full press release.